加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$63.7201
−US$0.0999 · -0.16%
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
常规交易时段
US$63.7201
−US$0.0999 · -0.16%
盘中时间采用ET。市场数据可能有所延迟。
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
日内区间
当前US$63.7201
52周区间
当前US$63.7201
盘中时间采用ET。市场数据可能有所延迟。
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
日内区间
当前US$63.7201
52周区间
当前US$63.7201
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.28亿 USD | 3.05亿 USD | 2.03亿 USD | 2.35亿 USD | 2.12亿 USD |
| 销货成本 | 1.29亿 USD | 1.11亿 USD | 1.13亿 USD | 2.61亿 USD | 2.29亿 USD |
| 毛利 | 2.98亿 USD | 1.94亿 USD | 9000.6万 USD | −2675万 USD | −1660.2万 USD |
| 研究与开发 | 7202.6万 USD | 4572.2万 USD | 5826.6万 USD | 8620.3万 USD | 1.05亿 USD |
| 销售、一般及管理费用 | 2.39亿 USD | 1.68亿 USD | 1.95亿 USD | 3.38亿 USD | 3.19亿 USD |
| 营业费用 | 3.11亿 USD | 2.18亿 USD | 2.71亿 USD | 6.41亿 USD | 4.3亿 USD |
| 利息收入 | — | — | 111.4万 USD | 254.1万 USD | 7.9万 USD |
| 利息支出 | 253.9万 USD | 303.2万 USD | — | 320.7万 USD | 283.5万 USD |
| 折旧和摊销 | 2522.4万 USD | 2195.3万 USD | 3373.4万 USD | 5930.9万 USD | 2180.7万 USD |
| 营业利润 | −1180.2万 USD | −2321.3万 USD | −1.81亿 USD | −6.68亿 USD | −4.46亿 USD |
| 净利润 | −2102.1万 USD | −5228.6万 USD | −1.76亿 USD | −5.49亿 USD | −2.45亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$81.00
上涨空间 27.12%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年5月4日 | 1:33 | — | — |
已生效 2023年5月4日
1:33
报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK5771.87万0.88%79.17亿 USD0.75%US$87.305-0.81%
Vanguard Morningstar Total Stock Market ETFVTI5154.52万0.00%2.3万亿 USD0.03%US$380.79-0.20%
ARK Genomic Revolution ETFARKG3297.02万1.60%22.19亿 USD0.75%US$48.82-1.33%
iShares Russell 2000 ETFIWM3275.33万0.04%787.4亿 USD0.19%US$276.09-0.65%
Vanguard Extended Market ETFVXF2162.89万0.02%954亿 USD0.05%US$231.84-0.72%
iShares Russell 2000 Growth ETFIWO1178万0.09%139.17亿 USD0.24%US$350.53-0.90%
Fidelity Enhanced Small Cap ETFFESM1059.03万0.16%64.1亿 USD0.28%US$44.985-0.56%
Vanguard Russell 2000 ETFVTWO974.91万0.05%180亿 USD0.06%US$111.5-0.69%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
